Is time to treat for HCV all the HIV/HCV co-infected hemophiliacs?
Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection is a major problem for hemophiliacs treated before 1985 with non-virally inactivated factor concentrates. However, as HIV infection has been effectively controlled by highly active antiretroviral therapy (HAART), HCV eradication has become a primary goal in co-infected individuals in order to prevent the progression to cirrhosis and end-stage liver failure and the development of hepatocellular carcinoma. In this concise review, the current knowledge as regards the management of HCV infection in HIV co-infected hemophiliacs is analyzed.
Franchini
Massimo
M
Hemophilia Center, City Hospital of Verona, Verona, Italy. mfranchini@univr.it
D019380:Anti-HIV Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000209:etiology / Q000517:prevention & control; D019090:Case Management; D002986:Clinical Trials as Topic; D015331:Cohort Studies; D018450:Disease Progression; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006467:Hemophilia A / Q000150:complications* / Q000628:therapy; D006526:Hepatitis C / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use; D007372:Interferons / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000209:etiology / Q000517:prevention & control; D017093:Liver Failure / Q000209:etiology / Q000517:prevention & control; D008113:Liver Neoplasms / Q000209:etiology / Q000517:prevention & control; D015337:Multicenter Studies as Topic; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000627:therapeutic use; D011446:Prospective Studies; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use
D019380:Anti-HIV Agents; D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; D007372:Interferons; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a